Skip to content

SPARK THERAPEUTICS, INC.: 10-Q filed 2017-11-07

What SPARK THERAPEUTICS, INC. reported in its quarterly report filed 2017-11-07 (fiscal Q3 2017): 31 published measures, 82 facts as tagged in accession 0001609351-17-000114.

This filing

Form
10-Q (quarterly report)
Filed
2017-11-07
Fiscal period
fiscal Q3 2017
Accession
0001609351-17-000114 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SPARK THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-30612,668,183USD
At 2016-12-31373,862,795USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-09-3042,263,207USD
At 2016-12-3143,586,082USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-30570,404,976USD
At 2016-12-31330,276,713USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-30146,434,119USD
At 2016-12-3158,923,097USD
At 2016-09-3090,615,538USD
At 2015-12-31293,530,590USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-65,011,911USD92
2017-01-01 to 2017-09-30-191,661,024USD273
2016-07-01 to 2016-09-30-32,562,407USD92
2016-01-01 to 2016-09-30-86,815,233USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-09-308,895,165USD273
2016-01-01 to 2016-09-307,466,103USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-07-01 to 2017-09-301,899,575USD92
2017-01-01 to 2017-09-304,657,275USD273
2016-07-01 to 2016-09-301,302,789USD92
2016-01-01 to 2016-09-303,880,046USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-30-444,041,935USD
At 2016-12-31-252,380,911USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-07-01 to 2017-09-30292,402USD92
2017-01-01 to 2017-09-30-1,816,323USD273
2016-07-01 to 2016-09-300USD92
2016-01-01 to 2016-09-300USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-09-3025,364,940USD
At 2016-12-3119,794,306USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-09-3033,835,069USD273
2016-01-01 to 2016-09-3017,301,617USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-65,832,254USD92
2017-01-01 to 2017-09-30-195,707,653USD273
2016-07-01 to 2016-09-30-33,131,274USD92
2016-01-01 to 2016-09-30-87,978,066USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-30489,142,949USD
At 2016-12-31314,593,677USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-3030,969,421USD
At 2016-12-3129,997,540USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-09-309,561,865USD
At 2016-12-319,928,737USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2017-09-301,236,817USD
At 2016-12-311,160,104USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2017-01-01 to 2017-09-30632,873USD273
2016-01-01 to 2016-09-300USD274

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-07-01 to 2017-09-3067,731,829USD92
2017-01-01 to 2017-09-30200,364,928USD273
2016-07-01 to 2016-09-3034,434,063USD92
2016-01-01 to 2016-09-3091,858,112USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-07-01 to 2017-09-3039,341,386USD92
2017-01-01 to 2017-09-30104,678,902USD273
2016-07-01 to 2016-09-3022,384,109USD92
2016-01-01 to 2016-09-3060,257,545USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-3036,926,603shares
At 2016-12-3130,864,224shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-09-301,015,363,029USD
At 2016-12-31583,973,682USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-09-30232,444USD
At 2016-12-31-794,296USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-30723,806USD
At 2016-12-31924,579USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-09-3015,677,442USD
At 2016-12-3113,826,920USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-09-304,443,407USD
At 2016-12-311,647,008USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2017-09-300USD
At 2016-12-311,000,235USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-64,719,509USD92
2017-01-01 to 2017-09-30-193,477,347USD273
2016-07-01 to 2016-09-30-32,562,407USD92
2016-01-01 to 2016-09-30-86,815,233USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-65,430,508USD92
2017-01-01 to 2017-09-30-190,634,284USD273
2016-07-01 to 2016-09-30-32,690,353USD92
2016-01-01 to 2016-09-30-86,869,049USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-3026,640,443USD92
2017-01-01 to 2017-09-3074,782,867USD273
2016-07-01 to 2016-09-3012,049,954USD92
2016-01-01 to 2016-09-3031,600,567USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-09-303,498,657USD273
2016-01-01 to 2016-09-302,613,420USD274

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2017-01-01 to 2017-09-30-1,816,323USD273
2016-01-01 to 2016-09-300USD274

Inspect the source

Entity
SPARK THERAPEUTICS, INC. / CIK 0001609351
Captured
SEC response SHA-256
7fe632d855eed754412cbe5e778ed6aaccb00c4b0d20a4d3c728df0af3a78c9c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001609351.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))